Somatropin / HGH

What it is

Somatropin is recombinant human growth hormone. The July 2025 GENOTROPIN label describes a 191-amino-acid protein made in Escherichia coli with the same sequence as pituitary human growth hormone. That exact identity does not turn every growth-hormone claim into an approved use.

“HGH” and “human growth hormone” are ambiguous reader terms. They may refer to the endogenous hormone, the active ingredient somatropin, a specific approved product, or an unidentified marketed material. A shared ingredient does not make brands, devices, excipients, concentrations, stability, storage histories, compounded preparations, or unidentified products interchangeable.

Why people care

Somatropin is a real prescription medicine, which makes it easy for anti-aging and performance claims to borrow the authority of approved replacement therapy. The central distinction is population: restoring growth hormone in someone with a defined deficiency is not the same question as giving it to a healthy, non-deficient person.

What humans actually show

• GENOTROPIN adult-deficiency trials: The label summarizes six randomized placebo-controlled trials involving 172 adults with growth hormone deficiency. During six months of double-blind treatment, GENOTROPIN increased lean body mass, total body water, and the lean-to-fat ratio and reduced body fat and waist circumference compared with placebo. These are replacement results in a deficient population, and body composition does not establish strength, performance, or longevity.
• Adult-onset deficiency trial: A 12-month randomized placebo-controlled trial enrolled 166 adults with adult-onset growth hormone deficiency. Treatment reduced total and trunk fat, increased lean mass, and improved total and LDL cholesterol, but did not significantly improve strength and endurance, quality of life, or bone mineral density.
• Healthy older men: In a six-month randomized double-blind trial of 52 healthy men older than 69, recombinant human growth hormone increased lean mass and reduced fat mass but did not improve knee or grip strength or systemic endurance. Adverse effects were more frequent, and some recipients required dose reduction.
• Growth hormone with or without testosterone: An 80-person factorial trial in healthy men aged 65 to 80 found that growth hormone alone increased lean mass. Several other findings occurred only with the combination, strength changes were variable, and bodily pain increased with growth hormone alone. Combination findings cannot be attributed to growth hormone alone.

Mechanistic and nonhuman evidence

The label describes linear-growth effects in indicated pediatric populations, normalization of IGF-1 in growth hormone deficiency, changes in protein, carbohydrate, lipid, and mineral metabolism, and retention of sodium, potassium, and phosphorus. These effects help explain intended actions and some risks; they do not authorize an unapproved use.

The label also summarizes rat and rabbit reproductive studies. Those animal records do not establish human reproductive safety or support anti-aging, performance, or recovery claims.

FDA and U.S. status

FDA-approved somatropin products exist. The July 2025 GENOTROPIN label covers defined pediatric growth-failure indications and replacement of endogenous growth hormone in adults with confirmed growth hormone deficiency.

That approval is not a general anti-aging, muscle-gain, fat-loss, athletic-performance, or recovery approval. FDA also states that compounded drugs are not FDA approved; an approved somatropin label cannot validate a compounded or unidentified “HGH” product.

Risks and warning limits

The reviewed label includes increased mortality in non-growth-hormone-deficient adults with acute critical illness after major surgery, trauma, or acute respiratory failure; fatalities in certain children with Prader-Willi syndrome; neoplasm monitoring; impaired glucose tolerance and diabetes; intracranial hypertension; severe hypersensitivity; fluid retention, edema, arthralgia, carpal-tunnel symptoms, and myalgia; hypoadrenalism and hypothyroidism; slipped capital femoral epiphysis; scoliosis progression; lipoatrophy; and pancreatitis.

These are label boundaries for defined products and populations, not a prediction for an unidentified product or an individual reader.

What remains unknown

• Whether somatropin provides a patient-important anti-aging, performance, or recovery benefit in healthy non-deficient people.
• The long-term benefit-to-risk balance for those non-approved uses.
• Whether a body-composition change translates into lower disability, morbidity, or mortality.
• The identity and quality of any unspecified HGH or compounded product.
• Interaction safety outside labeled and directly studied boundaries.

Product identity and quality limits

Endogenous human growth hormone and recombinant somatropin are related but not the same product category. Approved brands can differ in devices, diluents, excipients, concentrations, and storage requirements. A product labeled “HGH” is not authenticated by its name, and an approved label cannot be transferred to a compounded or unidentified product.

What has been studied together

The GENOTROPIN label carries specific boundaries for glucocorticoids, oral estrogen, insulin and other antihyperglycemic medicines, and drugs metabolized by CYP450 enzymes. It notes that formal interaction studies were not conducted for the CYP450 statement. These label directions are not a general compatibility finding.

The healthy-older-men trial directly studied growth hormone with testosterone. It is narrow coadministration evidence in one population, not support for other hormone combinations, “stacks,” or unidentified products.

What people are hearing

• “Because HGH is approved, it is an approved anti-aging treatment.” Somatropin approvals are product- and indication-specific.
• “More lean mass means more strength and better function.” Healthy-older-adult trials separated body-composition changes from functional outcomes.
• “Anything sold as HGH is equivalent to a prescription product.” A name does not establish product identity or quality.

Questions readers raise

Readers ask whether approved growth hormone can be transferred to anti-aging, whether lean mass proves muscle function, and whether products sharing an HGH label are equivalent. These are questions to investigate, not treatment recommendations. PepCurrent has not published anecdotal theme counts or public user reviews for this profile.

What would change this answer

• Replicated trials in healthy non-deficient adults with patient-important functional, morbidity, or mortality outcomes.
• Longer-term benefit-risk evidence for a defined product and population.
• A materially revised FDA label or new approved indication.
• Product-specific analytical and manufacturing evidence for an unidentified HGH material.

Sources and records

• FDA GENOTROPIN prescribing information, revised July 2025
• Drugs@FDA exact active-ingredient search for somatropin
• FDA compounding questions and answers
• Healthy older men trial — PMID 8633830
• Adult-onset growth hormone deficiency trial — PMID 15126520
• Growth hormone with or without testosterone trial — PMID 16332938
• Reproducible ClinicalTrials.gov somatropin search
• Reproducible human-record PubMed search